Abivax
Paris, New York, United States · Biopharma, Biotechnology, Consulting
Abivax is developing therapies that modulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body’s natural immune system mechanisms to treat diseas
Key facts
- Headquarters
- Paris, New York, United States
- Employees
- 69
- Industries
- Biopharma, Biotechnology, Consulting
- Status
- Private
- Website
- abivax.com
- Company page
Recent activity at Abivax
- : ABIVAX Appoints New Chief Medical Officer and Chief Technical Officer
- : Abivax SA Appoints Chris Rabbat as Chief Marketing Officer and Tim Kelly as Chief Technology Officer
- : Abivax Appoints James Berger as Global Head of Marketing
- : ABIVAX Appoints Michael Nesrallah as Chief Commercial Officer
- : Dechert Partners with Wharton School for Business Training Program
- : Dechert Advises Abivax On Its Successful €49.2 Million Financing
Abivax funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2022 | Funding Round | $49.2M |
Leadership
- Pierre Courteille, Chief Commercial Officer & Vice President Business Development
- New Chief Medical Officer, Chief Medical Officer
- Tim Kelly, Chief Technology Officer
- Chris Rabbat, Chief Marketing Officer
- James Berger, Head of Marketing
- Marc Garidel, Chief Executive Officer
- Pierre Courteille, Chief Business Officer
- Michael Nesrallah, Chief Commercial Officer
- Hartmut J. Ehrlich, Chief Executive Officer
Verified email and direct lines for Abivax ’s decision-makers are on Fundz. See plans
Employee benefit plans
Abivax files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Abivax in the news
- ABIVAX Société Anonyme (ABVX) stock price, news, quote and history - Yahoo Finance Australia (Oct 01, 2026)
- Biotech takeover target Abivax sinks over 43% as cancer cases cloud trial data for bowel disease drug - cnbc.com (Jun 02, 2026)
- StockWatch: New UC Data Sparks Smoother Sailing for Abivax - Genetic Engineering and Biotechnology News (Jul 05, 2026)
- Abivax Bowel-Disease Drug Hits Goals in Trial, But Shares Plunge on Safety Worries - WSJ (Jun 02, 2026)
- Abivax: Obefazimod Goes The Distance And So Does My Buy Rating - Seeking Alpha (Jul 16, 2026)
- Abivax CEO says $920M raise funds U.S. drug launch without Big Pharma - qz.com (Jul 10, 2026)
- Abivax raises $800M as dilution hits 8% and cash reaches 2029 - Stock Titan (Jul 01, 2026)
- Abivax CEO dismisses 'noise' around rumored Eli Lilly bid - Reuters (Jan 20, 2026)
Companies similar to Abivax
- Bristol Myers Squibb · Biopharma, Biotechnology, Health Care, Legal, Medical, Pharmaceutical, Therapeutics
- NRx Pharmaceuticals · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Citius Oncology · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Aculys Pharma · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
About Abivax : questions and answers
What does Abivax do?
Abivax is developing therapies that modulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body’s natural immune system mechanisms to treat diseas
Where is Abivax headquartered?
Abivax is headquartered in Paris, New York, United States.
How many employees does Abivax have?
Abivax has about 69 employees.
Has Abivax raised funding?
Yes. Fundz has recorded 1 funding event for Abivax . The most recent, Funding Round of $49.2M, was in Sep 2022.
Who leads Abivax ?
Pierre Courteille is a Chief Commercial Officer & Vice President Business Development at Abivax .
What is the latest news on Abivax ?
On Sep 26, 2026, ABIVAX Appoints New Chief Medical Officer and Chief Technical Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy